This innovative analytical approach could establish a novel classification system for cancer heterogeneity, potentially enhancing predictions of therapeutic efficacy in HER2-positive breast cancer and demonstrating clinical applicability. The gene discussed is ERBB2; the disease is breast carcinoma.